1. AHRO : Austin Health Research Online

Ashish Srinivasan

View Statistics Email Alert RSS Feed
 Claim profile

Profile

Loading... 2 0 20 0 false
Credit Name
Ashish Srinivasan
Full Name
Srinivasan, Ashish
 
Department
 
ORCID
Loading... 3 0 20 0 false

Publications

Refined By:
Author:  van Langenberg, Daniel R

Results 1-6 of 6 (Search time: 0.004 seconds).

Publication YearTitleAuthor(s)
1May-2023Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses.Srinivasan, Ashish ; De Cruz, Peter P ; Sam, Melissa; Toong, Catherine; van Langenberg, Daniel R
2Sep-2021Editorial: does anti-TNF "treatment persistence" always equate to "effective treatment"? Only objective disease assessments can answer the question.Srinivasan, Ashish ; van Langenberg, Daniel R
3Apr-2021Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach.Srinivasan, Ashish ; De Cruz, Peter P ; van Langenberg, Daniel R
4Aug-2020Letter: ustekinumab dose intensification for loss of response-should we re-induce before shortening the dose interval?Srinivasan, Ashish ; De Cruz, Peter P ; van Langenberg, Daniel R
5Aug-2020Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail.Srinivasan, Ashish ; De Cruz, Peter P ; van Langenberg, Daniel R
6Jun-2020A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease.Srinivasan, Ashish ; van Langenberg, Daniel R; Little, Robert D; Sparrow, Miles P; De Cruz, Peter P ; Ward, Mark G